Literature DB >> 20110453

Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis.

Philippe Szankasi1, David W Bahler.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia affecting adults in the western world. The clinical course of CLL is highly variable: cases that express mutated immunoglobulin heavy chain variable regions (IgV(H)) typically have a more indolent clinical course compared with those with unmutated IgV(H). The use of the V(H)3-21 variable region has also been found to confer a poor prognosis, independent of mutation status. Here we describe an assay for the identification of the expressed V(H) segment and its mutation status in CLL. This test uses whole blood-derived RNA and PCR primers annealing to the leader regions and the joining region segments. This approach allows more accurate determination of the IgV(H) mutation status relative to using framework region specific V(H) primers. An additional primer specific for the leader region of the V(H)3-21 segment is described and is shown to be necessary to identify this diagnostically important variable region. We successfully analyzed 99 of 103 samples, including five expressing the V(H)3-21 variable region. Approximately 5% of cases had complement determining region 3 sequences similar to previously reported cases, and overrepresentation of the V(H)1-69 segment was observed among unmutated cases. These results confirm the proper functioning and high success rate of this valuable prognostic for CLL designed for the use in a clinical laboratory setting.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110453      PMCID: PMC2871732          DOI: 10.2353/jmoldx.2010.090091

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  Biclonal chronic lymphocytic leukemia.

Authors:  E D Hsi; G Hoeltge; R R Tubbs
Journal:  Am J Clin Pathol       Date:  2000-06       Impact factor: 2.493

Review 2.  Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL.

Authors:  Tait D Shanafelt; Susan M Geyer; Neil E Kay
Journal:  Blood       Date:  2003-10-23       Impact factor: 22.113

3.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.

Authors:  Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Adrian Wiestner; Andreas Rosenwald; Peter W Thomas; Terry J Hamblin; Louis M Staudt; David G Oscier
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

4.  Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.

Authors:  M J Campbell; A D Zelenetz; S Levy; R Levy
Journal:  Mol Immunol       Date:  1992-02       Impact factor: 4.407

5.  Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Authors:  Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

6.  Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols.

Authors:  Christine Matthews; Mark Catherwood; T C M 'Curly' Morris; H Denis Alexander
Journal:  Leuk Lymphoma       Date:  2004-09

7.  Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.

Authors:  George F Widhopf; Laura Z Rassenti; Traci L Toy; John G Gribben; William G Wierda; Thomas J Kipps
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

8.  Lack of allelic exclusion in B cell chronic lymphocytic leukemia.

Authors:  L Z Rassenti; T J Kipps
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

9.  Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification.

Authors:  Carmela Gurrieri; Peter McGuire; Hong Zan; Xiao-Jie Yan; Andrea Cerutti; Emilia Albesiano; Steven L Allen; Vincent Vinciguerra; Kanti R Rai; Manlio Ferrarini; Paolo Casali; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

10.  Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia.

Authors:  Bradley T Messmer; Emilia Albesiano; Dimitar G Efremov; Fabio Ghiotto; Steven L Allen; Jonathan Kolitz; Robin Foa; Rajendra N Damle; Franco Fais; Davorka Messmer; Kanti R Rai; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2004-08-16       Impact factor: 14.307

View more
  3 in total

Review 1.  IGHV mutational status testing in chronic lymphocytic leukemia.

Authors:  Jennifer Crombie; Matthew S Davids
Journal:  Am J Hematol       Date:  2017-07-29       Impact factor: 10.047

2.  Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.

Authors:  Sophie A Herbst; Mattias Vesterlund; Alexander J Helmboldt; Rozbeh Jafari; Ioannis Siavelis; Matthias Stahl; Eva C Schitter; Nora Liebers; Berit J Brinkmann; Felix Czernilofsky; Tobias Roider; Peter-Martin Bruch; Murat Iskar; Adam Kittai; Ying Huang; Junyan Lu; Sarah Richter; Georgios Mermelekas; Husen Muhammad Umer; Mareike Knoll; Carolin Kolb; Angela Lenze; Xiaofang Cao; Cecilia Österholm; Linus Wahnschaffe; Carmen Herling; Sebastian Scheinost; Matthias Ganzinger; Larry Mansouri; Katharina Kriegsmann; Mark Kriegsmann; Simon Anders; Marc Zapatka; Giovanni Del Poeta; Antonella Zucchetto; Riccardo Bomben; Valter Gattei; Peter Dreger; Jennifer Woyach; Marco Herling; Carsten Müller-Tidow; Richard Rosenquist; Stephan Stilgenbauer; Thorsten Zenz; Wolfgang Huber; Eugen Tausch; Janne Lehtiö; Sascha Dietrich
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

3.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.